연구성과로 돌아가기
2023 연구자 정보 (55 / 1135)
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| Author Name | 제1저자 여부 | 교신저자 여부 | Address | ResearcherID | ORCID | Paper Title | WoS Edition | 최상위 JCR(%) | WoS Category | Related Email |
|---|---|---|---|---|---|---|---|---|---|---|
|
Chae, Heejung (Chae, H) |
|
|
[JCR상위 1.7] Prospective single-arm study of endocrine therapies with ovarian function suppression in premenopausal patients with node-positive early breast cancer with low genomic risk (INTERSTELLAR trial, KBCSG-25) | SCIE | 1.7 | ONCOLOGY | ||||
|
Chae, Yee Soo (Chae, YS) |
Kyungpook Natl Univ, Chilgok Hosp, Sch Med, Dept Hematol & Oncol, Daegu, South Korea Kyungpook Natl Univ, Dept Oncol Hematol, Med Ctr Biobank, Daegu, South Korea Kyungpook Natl Univ, Chilgok Hosp, Daegu, South Korea |
|
|
[JCR상위 1.7] Use of tumoral LDH to predict residual tumor burden after neoadjuvant chemotherapy in breast cancer. [JCR상위 1.7] MELK and Del-1 as druggable targets in TNBC. [JCR상위 11.8] Ten-Year Oncologic Outcomes in T1-3N1 Breast Cancer After Targeted Axillary Sampling: A Retrospective Study [JCR상위 16.6] A phase Ia/Ib study of novel anti-ErbB3 monoclonal antibody, barecetamab (ISU104) in refractory solid cancers and monotherapy or in combination with cetuximab in recurrent or metastatic head and neck cancer [JCR상위 1.1] T-DXd vs TPC in patients with HER2-low unresectable and/or metastatic BC in Asian subgroup: Results of DESTINY-Breast04 [JCR상위 3.5] Cardiac Safety and Efficacy of SB3 Trastuzumab Biosimilar for ERBB2-Positive Early Breast Cancer: Secondary Analysis of a Randomized Clinical Trial |
SCIE | 1.1 |
ONCOLOGY ONCOLOGY;SURGERY MEDICINE, GENERAL & INTERNAL |
phy123@knu.ac.kr; sbkim3@amc.seoul.kr; x.pivot@icans.eu; |
||
|
Chae, Yeesoo (Chae, Y) |
|
|
[JCR상위 1.7] Trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with HER2-low, hormone receptor-positive (HR plus ) unresectable and/or metastatic breast cancer (mBC): Exploratory biomarker analysis of DESTINY-Breast04 | SCIE | 1.7 | ONCOLOGY | ||||
|
Chae, Young Kwang (Chae, YK) |
Northwestern Univ, Feinberg Sch Med, Chicago, IL 60208 USA Northwestern Univ, Feinberg Sch Med, Chicago, IL USA Northwestern Univ, Feinberg Sch Med, Dept Internal Med Hematol & Oncol, 645 N Michigan Ave,Suite 1006, Chicago, IL 60611 USA Northwestern Mem Hosp, Dept Internal Med, Chicago, IL 60611 USA |
|
|
[JCR상위 1.7] Post-double lung transplantation survival outcomes of bilateral lung cancer and incidence of post-transplant lung cancer [JCR상위 1.7] Incidence, landscape and survival outcome of de novo malignancy after double lung transplantation. [JCR상위 67.0] Survival Outcomes After Double-Lung Transplantation for Refractory Lung-Limited Cancers and Incidence of Post-Transplant Lung Cancer [JCR상위 21.0] Current and future role of double-lung transplantation for bilateral lung cancer [JCR상위 19.0] A Comprehensive Landscape of De Novo Malignancy After Double Lung Transplantation [JCR상위 1.7] Machine learning models based on radiomics features to predict treatment response, biomarker status, and bone metastasis in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs) |
SCIE | 1.7 |
ONCOLOGY SURGERY;TRANSPLANTATION IMMUNOLOGY;TRANSPLANTATION |
ankit.bharat@nm.org;ychae@nm.org; ankit.bharat@nm.org;YCHAE@nm.org; ychae@nm.org; |
||
|
Chaney, Marya F. (Chaney, MF) |
|
|
[JCR상위 1.7] Phase 2 study of bavituximab (bavi), a first-in-class antibody targeting phosphatidylserine (PS), plus pembrolizumab (P) in advanced gastric or gastroesophageal junction (GEJ) cancer | SCIE | 1.7 | ONCOLOGY | ||||
|
Chau, Ian (Chau, I) |
ABC-2023-2020 Chau, Ian |
0000-0003-0286-8703 Chau, Ian |
[JCR상위 1.7] Phase 2 study of bavituximab (bavi), a first-in-class antibody targeting phosphatidylserine (PS), plus pembrolizumab (P) in advanced gastric or gastroesophageal junction (GEJ) cancer | SCIE | 1.7 | ONCOLOGY | ||||
|
Chen, Jen-Shi (Chen, JS) |
GLV-3349-2022 Chen, Jen-Shi |
|
[JCR상위 1.7] ATTRACTION-5: A phase 3 study of nivolumab plus chemotherapy as postoperative adjuvant treatment for pathological stage III (pStage III) gastric or gastroesophageal junction (G/GEJ) cancer [JCR상위 1.7] Phase 2 study of bavituximab (bavi), a first-in-class antibody targeting phosphatidylserine (PS), plus pembrolizumab (P) in advanced gastric or gastroesophageal junction (GEJ) cancer |
SCIE | 1.7 | ONCOLOGY | ||||
|
Chen, Li-Tzong (Chen, LT) |
|
|
[JCR상위 1.7] ATTRACTION-5: A phase 3 study of nivolumab plus chemotherapy as postoperative adjuvant treatment for pathological stage III (pStage III) gastric or gastroesophageal junction (G/GEJ) cancer | SCIE | 1.7 | ONCOLOGY | ||||
|
Cheng, Ann-Lii (Cheng, AL) |
Natl Taiwan Univ, Canc Ctr, Taipei, Taiwan Natl Taiwan Univ Hosp, Taipei, Taiwan |
ACM-0936-2022 Cheng, Ann-Lii |
|
[JCR상위 1.7] Outcomes by occurrence of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC) [JCR상위 0.2] Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3trial |
SCIE | 0.2 |
ONCOLOGY MEDICINE, GENERAL & INTERNAL |
pierce.chow@duke-nus.edu.sg; | ||
|
Cheon, Jaekyung (Cheon, J) |
Univ Ulsan, Ulsan Univ Hosp, Dept Internal Med, Div Hematol & Oncol,Coll Med, Ulsan, South Korea CHA Univ, CHA Bundang Med Ctr, Dept Med Oncol, Sch Med, Seongnam, South Korea |
|
|
[JCR상위 1.7] Serum vitamin D3 levels and overall survival (OS) in patients (pts) with advanced biliary tract cancer (BTC): Analysis of the NIFTY trial cohort. [JCR상위 3.6] Treatment With Liposomal Irinotecan Plus Fluorouracil and Leucovorin for Patients With Previously Treated Metastatic Biliary Tract Cancer The Phase 2b NIFTY Randomized Clinical Trial [JCR상위 28.4] Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group (vol 54, pg 1, 2022) |
SCIE | 1.7 | ONCOLOGY | yooc@amc.seoul.kr; | ||
|
Cheun, Jong-Ho (Cheun, JH) |
|
|
[JCR상위 1.7] Omission of breast surgery for predicted pCR patients with MRI and vacuum-assisted biopsy in breast cancer after neoadjuvant chemotherapy: A multicenter, single-arm, non-inferiority trial (OPTIMIST trial) | SCIE | 1.7 | ONCOLOGY | ||||
|
Cho, Eun Young (Cho, EY) |
Wonkwang Univ Coll Med & Hosp, Iksan, South Korea Chungnam Natl Univ, Dept Pediat, Sch Med, Daejeon, South Korea Chungnam Natl Univ Hosp, Dept Pediat, Daejeon, South Korea |
KHD-4039-2024 Cho, EunYoung |
|
[JCR상위 1.7] The role of M2BPGi for screening of advanced hepatic fibrosis in elderly patients [JCR상위 23.4] The Prevalence of Symptomatic Congenital Cytomegalovirus Disease in Korea; A 15-Year Multicenter Study and Analysis of Big Data From National Health Insurance System [JCR상위 18.3] Genotype-phenotype correlation of X-linked Alport syndrome observed in both genders: a multicenter study in South Korea |
SCIE | 1.7 |
GASTROENTEROLOGY & HEPATOLOGY INFECTIOUS DISEASES;PEDIATRICS MULTIDISCIPLINARY SCIENCES |
noshin@hanyang.ac.kr; yaejeankim@skku.edu; yhahn@snu.ac.kr;cheonghi@snu.ac.kr; |
||
|
Cho, Hanbyeol (Cho, H) |
Kyungpook Natl Univ KNU, Sch Mat Sci & Engn, Daegu 41566, South Korea |
|
|
[JCR상위 1.7] High-performance self-powered color filter-free blue photodetector based on wide-bandgap halide perovskites | SCIE | 1.7 | MATERIALS SCIENCE, MULTIDISCIPLINARY;METALLURGY & METALLURGICAL ENGINEERING | wook2@knu.ac.kr; | ||
|
Cho, Heejin (Cho, H) |
Seoul Natl Univ, Coll Med, Seoul, South Korea |
|
|
[JCR상위 1.7] Similar recurrence after curative treatment of HBV-related HCC regardless of HBV replication activity | SCIE | 1.7 | GASTROENTEROLOGY & HEPATOLOGY | ksukorea@yuhs.ac; | ||
|
Cho, Hyun Woong (Cho, HW) |
Korea Univ, Guro Hosp, Dept Obstet & Gynecol, Seoul, South Korea |
AAS-3301-2021 Choi, Youn |
|
[JCR상위 1.7] Oregovomab and non-platinum chemotherapy in PARP inhibitor-resistant ovarian, fallopian tube, or primary peritoneal cancer patients not candidates for platinum retreatment: A multicenter, two-cohort, single-arm phase 2 trial (OPERA/KGOG 3065/APGOT-OV6) [JCR상위 7.7] A phase III randomized controlled trial in primary stage three and four ovarian cancer after interval cytoreductive surgery (FOCUS/KOV-HIPEC-04) |
SCIE | 1.7 |
ONCOLOGY OBSTETRICS & GYNECOLOGY;ONCOLOGY |
페이지 이동: